West Pharmaceutical Services (NYSE:WST – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.550-6.750 for the period, compared to the consensus estimate of 6.510. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $2.9 billion. West Pharmaceutical Services also updated its FY24 guidance to $6.55 to $6.75 EPS.
West Pharmaceutical Services Stock Up 15.4 %
Shares of WST traded up $44.21 during midday trading on Thursday, hitting $330.65. The stock had a trading volume of 1,983,070 shares, compared to its average volume of 558,379. The company has a 50 day simple moving average of $299.60 and a two-hundred day simple moving average of $322.81. West Pharmaceutical Services has a twelve month low of $265.00 and a twelve month high of $413.70. The firm has a market cap of $23.99 billion, a price-to-earnings ratio of 47.03, a price-to-earnings-growth ratio of 10.21 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. During the same period in the prior year, the business earned $2.11 EPS. The business’s revenue for the quarter was down 6.9% compared to the same quarter last year. On average, analysts anticipate that West Pharmaceutical Services will post 6.42 EPS for the current year.
Insider Buying and Selling at West Pharmaceutical Services
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Stories
- Five stocks we like better than West Pharmaceutical Services
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Are Penny Stocks a Good Fit for Your Portfolio?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What is a Dividend King?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.